Rheumnow Podcast

The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, CTD skin disorders. dermatology drugs, biologics, andJAK inhibitors - their use, efficacy and side effects.

Features Dr. Jack Cush, Editor at RheumNow.com.
Show Notes:

- 20 yr. Tx trends in 6583 #SSc pts. 2005 to 2025 endothelin receptor antagonists & prostanoids/prostacyclins from 3% to 28%. CCB & PDE-5 inh stable. CTX shifted to mycophenolate, RTX, & nintedanib. Steriods decr from 50% to 18% https://t.co/nrm1Ov285f https://t.co/ftLn3bGH72

Systemic sclerosis metanalysis of 31 studies (32,134 pts) shows malignancy risk signif increased (SIR 1.66; CI 1.32 - 2.08). Highest: esophageal, liver, cervical, lung, & Heme (SIR 3.35 - 13.95). 7.4 yr mean from SSc to CA dx. https://t.co/IhxvfkMqkf

RZV (Shingrix) response in 76 immunosuppressed SSc & 304 controls (CG) recv two RZV doses. High seroconversion seen in SSc but signif lower than CG (92.6% vs 99.7%, P 0.001), w/ lower concentration but comparable CMI, lower AE (74% vs 86%) https://t.co/ALlnVEZIAt https://t.co/kYYy2JIo2J

Raynauds: Using the Clinical Practice Research Datalink Aurum (PCP) database (1998 - 2023) the prevalence of Raynaud’s 894/100 000, or 158449 cases in 2023. More in elderly & females, less in blacks. Incidence rate 46/100K https://buff.ly/TLjMy21

Guidelines to Spot Cancer in High Risk Dermatomyositis

Psoriatic Arthritis: EULAR 2026

New, Advanced Therapies in Gout explores the rapidly evolving therapeutic landscape beyond conventional urate-lowering therapy. Join our expert panel as they discuss emerging approaches—including cytokine inhibition, uricase therapies, NLRP3 and URAT-1 inhibitors, and the potential role of GLP-1 receptor agonists and SGLT2 inhibitors—while addressing which patients are most likely to benefit, how these agents fit into current treatment algorithms, and whether novel mechanisms of action have the potential to transform gout management. Panelists: Dr. Herbert Baraf Dr. Ken Saag Dr. Naomi Schlesinger Dr. Jack Cush (moderator)

Dr. Robert Terkeltaub 3 New Things it Pays to Know About Gout Pathobiology

Dr. Nicola Dalbeth Outcomes of Tophaceous Gout 

Dr. Ted Mikuls Subclinical Inflammation in Intercritical Gout

Dr. Michael Pillinger Gout and Cardiovascular Disease: What's the Risk? What's the Connection?

Dr. John Fitzgerald Gout & Metabolic syndrome

Dr. Karon Jatuworpruk Predicting and managing gout flares in hospitalised patients

Dr. Richard Conway Bespoke Telehealth in Gout: A Missed Opportunity

Dr. Robert Terkeltaub Four things you need to know about allopurinol hypersensitivity syndrome 

Dr. Angelo Gaffo Challenges in Gout Diagnosis

Dr. Janet Pope Tips for safe use of allopurinol in patients with gout